AnaptysBio's core business segment revolves around the research, development, and clinical advancement of innovative immunology therapeutics. This includes a focus on antibody-based therapies targeting inflammatory diseases and immuno-oncology indications. The company employs its proprietary antibody discovery platform to generate fully human antibodies with optimized therapeutic potential. Key R&D activities involve preclinical studies, Phase 1, Phase 2, and Phase 3 clinical trials to evaluate the safety and efficacy of their drug candidates. Technologies such as somatic hypermutation and high-throughput screening are utilized to identify and optimize antibody leads. The therapeutic areas covered include dermatology, rheumatology, and oncology, with a focus on addressing unmet medical needs in these areas. The ultimate goal is to improve patient outcomes by providing targeted and effective treatments for immune-mediated diseases and cancer. Partnerships with major pharmaceutical companies like GlaxoSmithKline and Bristol-Myers Squibb are crucial for co-development and commercialization efforts.